The Role of Surgery in the Management of Recurrent or Persistent Non-seminomatous Germ Cell Tumors{A figure is presented}

Niels Erik B Jacobsen, Richard Foster

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To review the management of patients with non-seminomatous germ cell tumors (NSGCTs) with persistent or recurrent disease following primary or secondary therapy, with particular attention devoted to the role of surgery. Methods: A non-structured review of the literature until January 2007 was performed using the PubMed database. Results: The management of persistent or recurrent disease among patients with NSGCT depends on stage at presentation and relapse, serum tumor marker levels at relapse, prior therapy, and timing of relapse. Clinical stage I patients who relapse following active surveillance are usually treated with induction chemotherapy. Likewise, patients who relapse following primary retroperitoneal lymph node dissection (RPLND) are treated with induction chemotherapy based on the systemic pattern of recurrence. Advanced cases with residual radiographic disease >1 cm and normal tumor markers following induction chemotherapy are generally recommended for postchemotherapy surgical resection, whereas those with persistently elevated markers undergo salvage chemotherapy. Select patients with resectable disease and elevated serum tumor markers may be appropriate candidates for surgery. Based on intrinsic chemoresistance, the treatment of patients with advanced disease who relapse >2 yr (late relapse) following successful chemotherapy is primarily surgery. Conclusion: Patients with NSGCTs with persistent disease or recurrence within 2 yr of initial therapy remain highly curable. The prognosis of patients with late relapse is compromised based on tumor chemoresistance. The role of surgery in the management of recurrent disease is primarily limited to the postchemotherapy setting; however, in the context of late relapse it often represents the primary treatment.

Original languageEnglish
Pages (from-to)163-176
Number of pages14
JournalEAU-EBU Update Series
Volume5
Issue number4
DOIs
StatePublished - Aug 2007

Fingerprint

Recurrence
Induction Chemotherapy
Tumor Biomarkers
Nonseminomatous germ cell tumor
Biomarkers
Therapeutics
Drug Therapy
Disease Management
Lymph Node Excision
PubMed
Databases
Neoplasms

Keywords

  • Non-seminomatous germ cell tumor
  • Relapse
  • Retroperitoneal lymph node dissection

ASJC Scopus subject areas

  • Urology

Cite this

The Role of Surgery in the Management of Recurrent or Persistent Non-seminomatous Germ Cell Tumors{A figure is presented}. / Jacobsen, Niels Erik B; Foster, Richard.

In: EAU-EBU Update Series, Vol. 5, No. 4, 08.2007, p. 163-176.

Research output: Contribution to journalArticle

@article{64924a1aac114cae886e26e053180af2,
title = "The Role of Surgery in the Management of Recurrent or Persistent Non-seminomatous Germ Cell Tumors{A figure is presented}",
abstract = "Objective: To review the management of patients with non-seminomatous germ cell tumors (NSGCTs) with persistent or recurrent disease following primary or secondary therapy, with particular attention devoted to the role of surgery. Methods: A non-structured review of the literature until January 2007 was performed using the PubMed database. Results: The management of persistent or recurrent disease among patients with NSGCT depends on stage at presentation and relapse, serum tumor marker levels at relapse, prior therapy, and timing of relapse. Clinical stage I patients who relapse following active surveillance are usually treated with induction chemotherapy. Likewise, patients who relapse following primary retroperitoneal lymph node dissection (RPLND) are treated with induction chemotherapy based on the systemic pattern of recurrence. Advanced cases with residual radiographic disease >1 cm and normal tumor markers following induction chemotherapy are generally recommended for postchemotherapy surgical resection, whereas those with persistently elevated markers undergo salvage chemotherapy. Select patients with resectable disease and elevated serum tumor markers may be appropriate candidates for surgery. Based on intrinsic chemoresistance, the treatment of patients with advanced disease who relapse >2 yr (late relapse) following successful chemotherapy is primarily surgery. Conclusion: Patients with NSGCTs with persistent disease or recurrence within 2 yr of initial therapy remain highly curable. The prognosis of patients with late relapse is compromised based on tumor chemoresistance. The role of surgery in the management of recurrent disease is primarily limited to the postchemotherapy setting; however, in the context of late relapse it often represents the primary treatment.",
keywords = "Non-seminomatous germ cell tumor, Relapse, Retroperitoneal lymph node dissection",
author = "Jacobsen, {Niels Erik B} and Richard Foster",
year = "2007",
month = "8",
doi = "10.1016/j.eeus.2007.03.003",
language = "English",
volume = "5",
pages = "163--176",
journal = "EAU-EBU Update Series",
issn = "1871-2592",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - The Role of Surgery in the Management of Recurrent or Persistent Non-seminomatous Germ Cell Tumors{A figure is presented}

AU - Jacobsen, Niels Erik B

AU - Foster, Richard

PY - 2007/8

Y1 - 2007/8

N2 - Objective: To review the management of patients with non-seminomatous germ cell tumors (NSGCTs) with persistent or recurrent disease following primary or secondary therapy, with particular attention devoted to the role of surgery. Methods: A non-structured review of the literature until January 2007 was performed using the PubMed database. Results: The management of persistent or recurrent disease among patients with NSGCT depends on stage at presentation and relapse, serum tumor marker levels at relapse, prior therapy, and timing of relapse. Clinical stage I patients who relapse following active surveillance are usually treated with induction chemotherapy. Likewise, patients who relapse following primary retroperitoneal lymph node dissection (RPLND) are treated with induction chemotherapy based on the systemic pattern of recurrence. Advanced cases with residual radiographic disease >1 cm and normal tumor markers following induction chemotherapy are generally recommended for postchemotherapy surgical resection, whereas those with persistently elevated markers undergo salvage chemotherapy. Select patients with resectable disease and elevated serum tumor markers may be appropriate candidates for surgery. Based on intrinsic chemoresistance, the treatment of patients with advanced disease who relapse >2 yr (late relapse) following successful chemotherapy is primarily surgery. Conclusion: Patients with NSGCTs with persistent disease or recurrence within 2 yr of initial therapy remain highly curable. The prognosis of patients with late relapse is compromised based on tumor chemoresistance. The role of surgery in the management of recurrent disease is primarily limited to the postchemotherapy setting; however, in the context of late relapse it often represents the primary treatment.

AB - Objective: To review the management of patients with non-seminomatous germ cell tumors (NSGCTs) with persistent or recurrent disease following primary or secondary therapy, with particular attention devoted to the role of surgery. Methods: A non-structured review of the literature until January 2007 was performed using the PubMed database. Results: The management of persistent or recurrent disease among patients with NSGCT depends on stage at presentation and relapse, serum tumor marker levels at relapse, prior therapy, and timing of relapse. Clinical stage I patients who relapse following active surveillance are usually treated with induction chemotherapy. Likewise, patients who relapse following primary retroperitoneal lymph node dissection (RPLND) are treated with induction chemotherapy based on the systemic pattern of recurrence. Advanced cases with residual radiographic disease >1 cm and normal tumor markers following induction chemotherapy are generally recommended for postchemotherapy surgical resection, whereas those with persistently elevated markers undergo salvage chemotherapy. Select patients with resectable disease and elevated serum tumor markers may be appropriate candidates for surgery. Based on intrinsic chemoresistance, the treatment of patients with advanced disease who relapse >2 yr (late relapse) following successful chemotherapy is primarily surgery. Conclusion: Patients with NSGCTs with persistent disease or recurrence within 2 yr of initial therapy remain highly curable. The prognosis of patients with late relapse is compromised based on tumor chemoresistance. The role of surgery in the management of recurrent disease is primarily limited to the postchemotherapy setting; however, in the context of late relapse it often represents the primary treatment.

KW - Non-seminomatous germ cell tumor

KW - Relapse

KW - Retroperitoneal lymph node dissection

UR - http://www.scopus.com/inward/record.url?scp=34250648359&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250648359&partnerID=8YFLogxK

U2 - 10.1016/j.eeus.2007.03.003

DO - 10.1016/j.eeus.2007.03.003

M3 - Article

VL - 5

SP - 163

EP - 176

JO - EAU-EBU Update Series

JF - EAU-EBU Update Series

SN - 1871-2592

IS - 4

ER -